USA flag logo/image

An Official Website of the United States Government

Heterologous Production of Eleutherobin Precursors

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
70610
Program Year/Program:
2004 / STTR
Agency Tracking Number:
CA105899
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
AMYRIS BIOTECHNOLOGIES
AMYRIS BIOTECHNOLOGIES 412 B KAINS AVE ALBANY, CA 94706 0126
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2004
Title: Heterologous Production of Eleutherobin Precursors
Agency: HHS
Contract: 1R41CA105899-01
Award Amount: $99,495.00
 

Abstract:

DESCRIPTION (provided by applicant): Terpenoids are a diverse class of natural compounds with equally diverse and potent bioactivities. Because the practical use of terpenoids hinges on the ability to extract or synthesize these compounds, only the most abundant or easily synthesized compounds have been commercially developed. The long-term goal of this Small Business Technology Transfer Phase I project is to facilitate the clinical testing and use of new cancer compounds through the economical production of otherwise scarce terpenes. Eleutherobin and sarcodictyin A and B are cytotoxic terpenes that act in a manner analogous to very successful anti-cancer drug Taxol. Supply limitations, however, has precluded the development of these exciting compounds. This Phase I research will use innovative methods to identify, clone and express the terpene cyclase responsible for the formation of the eleutherobin carbon backbone. By detecting the activity of the cyclase, we will isolate and partially sequence the eunicellane cyclase. These partial sequences will then be used to design PCR probes to clone the full length cyclase gene. The sequence of the cyclase will act as a starting point in the discovery of the full biosynthetic pathway. As many compound produced by marine animals are the product of microbial symbionts, the cyclase gene allow the identification of biosynthetic gene clusters associated with our compound of interest. The discovery and expression of the identified biosynthetic pathway in bacteria that over-produce terpene precursors will allow the production of valuable terpenes in large scale fermentations. This research, conducted in collaboration with the University of California, will contribute to the expanding field of terpene cyclase structure, function and evolution and will provide educational opportunities for graduate and under-graduate students. This technology could result in the development of promising new terpene-based drugs produced at a lower cost to consumers and to the environment, in terms of destruction of natural resources and the release of synthetic chemical effluents.

Principal Investigator:

Neil S. Renninger
5105043995
NEIL.RENNINGER@ALUM.MIT.EDU

Business Contact:


5105043995
Small Business Information at Submission:

AMYRIS BIOTECHNOLOGIES
AMYRIS BIOTECHNOLOGIES 412 B KAINS AVE ALBANY, CA 94706

EIN/Tax ID: 550856151
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
UNIVERSITY OF CALIFORNIA BERKELEY
UNIVERSITY OF CALIFORNIA BERKELEY
Berkeley, CA 94720
RI Type: Nonprofit college or university